Amgen Optimistic About Growth, Despite Denosumab Biosimilars, Potential Tariffs
MariTide Phase II Obesity Details Planned For ADA
Amgen saw revenue rise 19% to $33.4bn in 2024 and said revenue should grow to $34.3bn-$35.7bn in 2025 despite losing exclusivity for its biggest franchise – Prolia and Xgeva (denosumab) – this year.
